-
National Health Commission issued ethics review measures (draft for comments)
Time of Update: 2021-07-16
Article 46: Institutions, institutional ethics review committees, and project researchers who violate the requirements of laws and regulations in carrying out human life science and medical research work shall be dealt with in accordance with relevant laws and regulations .
-
The National Health Commission issued a document stating that patients with chronic diseases are expected to get rid of the pain of repeated queuing to prescribe drugs
Time of Update: 2021-07-14
On March 24, the Medical Administration and Hospital Administration of the National Health Commission issued the “Notice on Doing a Good Job in the Management of Long-term Prescriptions for Chronic Diseases”, which stipulates that long-term medication (including special drugs such as narcotic drugs and psychotropic drugs), blood For chronically ill patients with stable conditions such as dialysis and other special treatments, the hospital can prescribe related drugs within 12 weeks at a time .
-
After continuously buying factories, where is the next growth point for WuXi Biologics?
Time of Update: 2021-07-14
Although WuXi Biologics chooses R&D in the global layout China's global production strategy is to try to obtain high gross profit in both sectors, but from the current business structure, CDMO is still the most important source of company income .
-
CPhI Pharma Online Urgent Purchase Product List 2020.03.24
Time of Update: 2021-07-14
cn] There will be free online purchasing matching activities every week.
If your company can provide the following products, please call or email us as soon as possible-the corresponding "serial number" or "name" of the product in the list; we will provide you with detailed procurement requirements and customer contact information .
-
National Health Commission: Nucleic acid testing and vaccination information will be integrated into the health code
Time of Update: 2021-07-14
Mao Qunan, director of the Planning Department of the National Health Commission, said at a press conference of the National Health Commission on the 23rd that the country has basically achieved "one code access".
-
A GSK executive was immediately fired for misconduct
Time of Update: 2021-07-13
It is reported that Christopher Corsico, senior vice president of GSK Development and current member of Galvani's board of directors, has been appointed as the new chairman of Galvani's board of directors .
-
Lost for 4 consecutive years!
Time of Update: 2021-07-13
On March 25, Hutchison Pharmaceuticals announced that it has reached an agreement with GL Mountrose Investment Two Limited, which is controlled and managed by Telford Capital, to sell its indirect non-core and non-consolidated non-prescription drug joint venture Guangzhou Baiyunshan Hutchison The entire equity of Huangpu Chinese Medicine Co.
-
The National Health Commission Medical Administration and Hospital Administration issued the "Long-term Prescription Management Standards"
Time of Update: 2021-07-12
The original text is as follows: Article 1 Standardize long-term prescription management, promote hierarchical diagnosis and treatment, promote rational use of drugs, and ensure medical quality and medical safety.
-
CPhI Pharma Online Urgent Purchasing Product List 2021.04.02
Time of Update: 2021-07-12
cn] There will be free online purchasing matching activities every week.
If your company can provide the following products, please call or email us as soon as possible-the corresponding "serial number" or "name" of the product in the list; we will provide you with detailed procurement requirements and customer contact information .
-
Heavy fines for API monopoly again, Tianyao shares fined 44.02 million yuan
Time of Update: 2021-07-11
(hereinafter referred to as (Referred to as "Weifang Huaxin") illegally controlled the antihypertensive compound reserpine raw material medicine, driving up prices and making huge profits, was confiscated of illegal gains and fined more than 7 million yuan .
-
The Health Commission has spoken about living a "tight life", and a large number of public hospitals have shrunk their budgets by 50 to 70%
Time of Update: 2021-07-11
According to data from the National Health Commission this time, the decline in health expenditure budgets of various public hospitals may further affect the payment cycle of medical consumables .
-
"Afraid of getting angry" Baiyunshan splits its tradable subsidiary's Hong Kong stocks to go public, is Wanglaoji not popular or Jinge is not strong?
Time of Update: 2021-07-11
On the evening of March 31, Baiyunshan issued an announcement stating that the Hong Kong Stock Exchange had confirmed that it could split and list Guangzhou Pharmaceutical .
The prospectus shows that the corresponding operating income of Guangzhou Pharmaceuticals during the reporting period of 2018, 2019, and 2020 was about 3.
-
Employee medical insurance personal accounts can be paid from 50% within the scope of the mutual aid policy of family members
Time of Update: 2021-07-10
The executive meeting of the State Council held on April 7 decided to establish and improve the measures to establish and improve the mutual aid guarantee mechanism of basic medical insurance for employees, broaden the use of personal account funds, and reduce the medical burden of the masses .
-
The new crown diagnosis and treatment plan is updated again after half a year. What has changed?
Time of Update: 2021-07-09
For patients who meet other conditions and continue to be positive for nucleic acid for more than 4 weeks, the "Plan" recommends that the patient be discharged after a comprehensive assessment of the patient's infectivity through antibody testing, virus culture and isolation and other methods .
-
Liaoning Publicly Solicits Opinions on the Implementation Rules for the Administration of Post-marketing Changes in Drugs
Time of Update: 2021-07-09
Article 2 These implementation rules are applicable to the post-marketing drug registration changes and drug production site changes that are implemented by the provincial drug regulatory department, and the relevant laws and regulations and related technical guidelines are clear, as well as those approved by the holder and the Liaoning Provincial Drug Supervision and Administration.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Gefitinib Tablets (No. 17 of 2021)
Time of Update: 2021-07-08
All manufacturers of gefitinib tablets shall submit supplementary applications for revision of the instructions for gefitinib tablets in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations and in accordance with the revision requirements of the instructions for gefitinib tablets (see appendix), on April 20, 2021 A few days ago, it was reported to the Drug Approval Center of the State Administration or the provincial drug regulatory authority for record .
-
Announcement of the State Food and Drug Administration on the conversion of Wei'an capsules to non-prescription drugs (No. 19 of 2021)
Time of Update: 2021-07-08
The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents .
doc of the National Medical Products Administration Annex 2 of the Announcement No.
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Huli Powder Preparations (No. 42 of 2021)
Time of Update: 2021-07-08
The marketing authorization holders of all the above-mentioned drugs shall revise the instructions in accordance with the requirements of the corresponding annexes in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and report to the provincial drug regulatory authority for record before June 14, 2021 .
-
Announcement of the State Food and Drug Administration on the revision of the drug inserts of 14 varieties including paracetamol and Mami Oral Solution (No. 57 of 2021)
Time of Update: 2021-07-08
The holder of the marketing authorization of this product shall submit a supplementary application for the revision of the label in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the label (see appendix), and submit it to the National Drug Administration before July 21, 2021 The Bureau’s Drug Evaluation Center or the Provincial Drug Supervision and Administration Department for the record .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Use of Misoprostol Tablets in Obstetrics and Gynecology (No. 29 of 2021)
Time of Update: 2021-07-08
The marketing authorization holder of this product shall submit a supplementary application for the revision of the label in accordance with the "Administrative Measures on Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the label for misoprostol tablets in obstetrics and gynecology (see attachment), in 2021 Before May 24, report to the Drug Evaluation Center of the State Drug Administration or the provincial drug regulatory authority for the record .
